Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPRENEX vs BUPRENORPHINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.
Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.
Treatment of opioid dependence,Management of moderate to severe pain (off-label)
Treatment of opioid dependence (Subutex, Suboxone),Moderate to severe pain (parenteral formulation, e.g., Buprenex),Off-label: Treatment of depression (as adjunctive therapy), chronic pain in opioid-tolerant patients, and neonatal abstinence syndrome (probable).
0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.
Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.
Terminal elimination half-life is 37 hours (range 20-70 hours) due to slow dissociation from mu-opioid receptors, contributing to prolonged clinical effects.
Terminal elimination half-life is 24-60 hours (mean ~37 hours) due to enterohepatic recirculation and slow dissociation from mu-opioid receptors. Clinically, this allows for every-other-day or thrice-weekly dosing in maintenance therapy.
Primarily N-dealkylation via CYP3A4; also conjugation by UGT enzymes (UGT1A1, UGT2B7).
Primarily hepatic via N-dealkylation to norbuprenorphine via CYP3A4, with minor contribution from CYP2C8; norbuprenorphine is active and further glucuronidated; undergoes extensive first-pass metabolism; mainly excreted in feces (as unchanged drug and metabolites) and to a lesser extent in urine.
Buprenorphine is primarily eliminated via fecal excretion (70%) as unchanged drug and metabolites, with renal excretion accounting for approximately 10-30% of the dose.
Buprenorphine is primarily eliminated via biliary excretion of its metabolites, with approximately 70% of the dose recovered in feces as unchanged drug and metabolites. Renal elimination accounts for about 10-30%, primarily as metabolites.
96% bound to alpha- and beta-globulins, and albumin.
Approximately 96% bound to alpha- and beta-globulins, with minimal binding to albumin.
Volume of distribution is 430-600 L (approximately 2.8 L/kg), indicating extensive tissue distribution.
Volume of distribution is 2-4 L/kg (mean ~3.2 L/kg). High Vd indicates extensive tissue distribution, including sequestration in brain and adipose tissue.
Sublingual: 30-50% (due to first-pass metabolism); buccal: 50-60%; oral: 15-30% (not clinically used); intravenous: 100%.
Sublingual: 30-55% (variable due to first-pass metabolism); Oral: ~15% (low due to extensive hepatic metabolism); Transdermal: ~15-20%; Intravenous/Intramuscular: 100%.
No specific dose adjustment required for GFR >30 m L/min; for GFR 15-30 m L/min, consider cautious dosing and extended intervals; for GFR <15 m L/min, use with caution and consider dose reduction.
No dosage adjustment required for mild to moderate impairment (GFR >30 m L/min). For severe impairment (GFR <30 m L/min), consider reducing dose and increasing interval; avoid in anuric patients.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and monitor; Child-Pugh C: avoid use or reduce dose by 75%.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% and monitor. Child-Pugh C: contraindicated or use with extreme caution with significant dose reduction (e.g., 50-75% reduction).
Not recommended for children under 2 years; for age 2-12 years: 2-6 mcg/kg intramuscularly or intravenously every 4-6 hours; maximum single dose 0.3 mg.
For pain (≥2 years): sublingual tablet 2-6 mcg/kg every 4-8 hours; IV/IM 2-6 mcg/kg every 4-6 hours. For opioid use disorder (≥16 years): induction 2-4 mg, then titration to 12-16 mg once daily; safety in <16 years not established.
Start with 0.15 mg intramuscularly or intravenously every 6 hours; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Initiate at lowest dose (e.g., sublingual 2 mg, transdermal 5 mcg/h) and titrate slowly due to increased sensitivity and risk of respiratory depression, falls, and cognitive impairment; monitor renal and hepatic function.
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of death with intravenous administration; risk of serious adverse events when used with benzodiazepines or other CNS depressants.
Risk of respiratory depression, particularly in non-opioid-tolerant patients; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy; risk of serious harm or death with concomitant use of benzodiazepines or CNS depressants; requirement for patient access to emergency medical services and monitoring; risk of addiction, abuse, and misuse; risk of accidental exposure.
Respiratory depression; CNS depression; risk of dependence and abuse; adrenal insufficiency; QT prolongation; severe injection site reactions; risk of precipitating withdrawal in opioid-dependent patients; neonatal withdrawal syndrome; impairment of ability to drive or operate machinery.
Respiratory depression: ceiling effect exists, but risk increases with non-opioid-tolerant use or coadministration of CNS depressants,Potentiation of respiratory depression by benzodiazepines and alcohol,Neonatal opioid withdrawal syndrome: avoid prolonged use during pregnancy unless necessary,Adrenal insufficiency: risk with prolonged use,Androgen deficiency: may occur with chronic use,Hypotension, especially in hypovolemic patients,Biliary tract spasm: may cause constriction of sphincter of Oddi,Risk of misuse, abuse, and diversion
Hypersensitivity to buprenorphine; significant respiratory depression; acute or severe asthma; GI obstruction; elevated CSF pressure; use of MAOIs within 14 days.
Hypersensitivity to buprenorphine or any component of the formulation,Significant respiratory depression in non-opioid-tolerant patients,Acute or severe bronchial asthma,Known or suspected gastrointestinal obstruction (including paralytic ileus),Monoamine oxidase inhibitor (MAOI) use within past 14 days (relative contraindication; may precipitate serotonin syndrome),Mild to moderate hepatic impairment: use with caution; severe hepatic impairment: contraindicated
No specific food interactions are reported. Grapefruit juice has not been shown to significantly alter buprenorphine metabolism. Advise patients to maintain a balanced diet to manage opioid-induced constipation.
No specific food interactions. Grapefruit juice may increase buprenorphine levels via CYP3A4 inhibition. Avoid excessive alcohol. Maintain a balanced diet to support overall health during treatment.
Buprenorphine (Buprenex) is classified as Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal loss and skeletal abnormalities at high doses. Second and third trimesters: Chronic use may lead to neonatal abstinence syndrome (NAS) and neonatal respiratory depression. Risk of preterm labor and low birth weight. Use only if benefit outweighs risk.
FDA Pregnancy Category C. First trimester: No clear evidence of major malformations in human studies, but animal studies show increased risk of neural tube defects and skeletal anomalies at high doses. Second and third trimesters: Risk of neonatal opioid withdrawal syndrome (NOWS) with chronic use; may cause fetal respiratory depression if used near term.
Buprenorphine is excreted into breast milk in low concentrations. The milk-to-plasma ratio (M/P) is approximately 0.5-0.9. Limited data suggest no adverse effects in breastfed infants at maternal doses up to 24 mg/day. However, monitor infant for sedation and respiratory depression. Benefits of breastfeeding outweigh risks in opioid-dependent mothers on maintenance therapy.
Buprenorphine is excreted into breast milk with a milk-to-plasma ratio of approximately 0.6 to 1.2. It is generally considered compatible with breastfeeding, but infants should be monitored for sedation and respiratory depression, especially in high maternal doses or with concomitant CNS depressants.
No specific dose adjustments are recommended for buprenorphine during pregnancy. However, due to increased plasma volume and hepatic clearance, some patients may require dose increases in the second and third trimesters to avoid withdrawal symptoms. Close monitoring of therapeutic response and withdrawal signs is advised.
No routine dose adjustment is recommended, but dose may need to be increased due to increased clearance and volume of distribution in pregnancy, particularly in the third trimester. Monitor for withdrawal symptoms (e.g., craving, anxiety, abdominal cramping) and consider incremental dose increases (by 2-4 mg) if needed. Postpartum, dose should be titrated back to prepregnancy level over 1-2 weeks.
Buprenorphine (Buprenex) is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer than full agonists in overdose. It has high affinity for mu-receptors, which can precipitate withdrawal if given to opioid-dependent patients. Monitor for respiratory depression, especially in combination with CNS depressants. Use with caution in hepatic impairment; adjust dose in moderate to severe impairment.
Buprenorphine is a partial mu-opioid agonist with a ceiling effect on respiratory depression, making it safer than full agonists in overdose. It has high affinity for mu receptors, which can precipitate withdrawal if given to opioid-dependent patients already on full agonists. Sublingual administration avoids first-pass metabolism. Monitor liver function due to hepatotoxicity risk, especially with injectable forms. Long half-life allows every-other-day dosing in maintenance therapy. Naloxone is added in combination products to deter intravenous abuse.
Do not stop taking this medication abruptly as it may cause withdrawal symptoms; follow your doctor's instructions for tapering.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, sedatives) as they can increase the risk of severe drowsiness or respiratory depression.,This medication can cause constipation; increase fluid and fiber intake, and consider stool softeners.,Store securely away from children and pets, as accidental ingestion can be fatal.,Do not drive or operate heavy machinery until you know how this medication affects you, as it may cause dizziness or drowsiness.
Take buprenorphine exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not use alcohol, benzodiazepines, or other sedatives while on buprenorphine as it can cause severe drowsiness, respiratory depression, or coma.,Avoid driving or operating heavy machinery until you know how buprenorphine affects you.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store safely out of reach of children; accidental ingestion can be fatal.,Inform your doctor if you have liver disease, breathing problems, or are pregnant.,If you miss a dose, take it as soon as possible; skip if almost time for next dose. Do not double dose.
No interactions on record
"Buprenorphine, a partial mu-opioid receptor agonist with ceiling effects on respiratory depression, coadministered with Ketobemidone, a full mu-opioid agonist, may produce additive central nervous system (CNS) depression. This synergistic effect can lead to profound sedation, respiratory depression, coma, and death, especially when doses are escalated or in the presence of other CNS depressants. The interaction is particularly dangerous due to buprenorphine's high affinity for mu receptors potentially displacing Ketobemidone and precipitating withdrawal, while simultaneously contributing to CNS depressant effects."
"Buprenorphine, a partial mu-opioid receptor agonist, and triflupromazine, a phenothiazine antipsychotic with strong central nervous system (CNS) depressant properties, exert additive CNS depression when coadministered. This can lead to excessive sedation, respiratory depression, hypotension, and increased risk of coma or death, particularly in elderly or compromised patients. The interaction reduces psychomotor function and may potentiate other adverse effects such as orthostatic hypotension and extrapyramidal symptoms."
"Buprenorphine, a partial mu-opioid receptor agonist, can inhibit CYP3A4 isoenzymes, thereby reducing the hepatic metabolism of Midostaurin, a multikinase inhibitor primarily metabolized by CYP3A4. This results in elevated plasma concentrations of Midostaurin, increasing the risk of dose-dependent toxicities such as QT prolongation, myelosuppression, and gastrointestinal adverse effects. Clinicians should monitor for signs of Midostaurin toxicity and consider dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPRENEX vs BUPRENORPHINE, answered by our medical review team.
BUPRENEX is a Opioid Partial Agonist that works by Partial agonist at mu-opioid receptors; weak antagonist at kappa-opioid receptors.. BUPRENORPHINE is a Opioid Partial Agonist that works by Partial mu-opioid receptor agonist and weak kappa-opioid receptor antagonist; also exhibits high affinity but low intrinsic activity at mu-opioid receptors, producing analgesia and euphoria with a ceiling effect on respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPRENEX and BUPRENORPHINE depend on the specific clinical indication. These are both Opioid Partial Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPRENEX is: 0.3 mg intramuscularly or intravenously every 6 hours as needed for pain; may repeat once after 30-60 minutes if needed.. The standard adult dose of BUPRENORPHINE is: Sublingual tablet: 2-8 mg every 6-8 hours as needed for pain; for opioid use disorder: 12-16 mg once daily. Transdermal patch: 5-20 mcg/h applied every 7 days. IV/IM: 0.3 mg every 6-8 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPRENEX and BUPRENORPHINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPRENEX is classified as Category C. Buprenorphine (Buprenex) is classified as Pregnancy Category C. First trimester: Limited human data; animal studies show increased fetal loss and skeletal abnormalities at high dos. BUPRENORPHINE is classified as Category C. FDA Pregnancy Category C. First trimester: No clear evidence of major malformations in human studies, but animal studies show increased risk of neural tube defects and skeletal ano. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.